Total Payments
$421,287
2024 Payments
$51,678
Companies
31
Transactions
477
Payment Breakdown by Category
Other$158,848 (37.7%)
Consulting$115,194 (27.3%)
Travel$48,398 (11.5%)
Research$47,870 (11.4%)
Education$38,286 (9.1%)
Food & Beverage$12,692 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $115,194 | 69 | 27.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,554 | 50 | 23.2% |
| Travel and Lodging | $48,398 | 133 | 11.5% |
| Unspecified | $47,870 | 24 | 11.4% |
| Education | $38,286 | 15 | 9.1% |
| Honoraria | $35,175 | 49 | 8.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,119 | 16 | 6.2% |
| Food and Beverage | $12,692 | 121 | 3.0% |
Payments by Type
General
$373,416
453 transactions
Research
$47,870
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Baxter Healthcare | $189,606 | 257 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $57,512 | 29 | $0 (2024) |
| Medtronic, Inc. | $42,652 | 25 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $30,719 | 66 | $0 (2024) |
| CHF Solutions, Inc | $22,926 | 21 | $0 (2020) |
| Covidien LP | $13,901 | 24 | $0 (2020) |
| Astute Medical, Inc. | $12,500 | 6 | $0 (2018) |
| Nuwellis, Inc. | $12,337 | 12 | $0 (2024) |
| Kaneka Pharma America LLC | $7,268 | 1 | $0 (2020) |
| Leadiant Biosciences, Inc. | $6,375 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,678 | 50 | Baxter Healthcare ($38,825) |
| 2023 | $27,895 | 30 | Baxter Healthcare ($11,840) |
| 2022 | $23,444 | 37 | Fresenius USA Marketing, Inc. ($9,019) |
| 2021 | $43,731 | 36 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($6,475) |
| 2020 | $40,299 | 31 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($12,306) |
| 2019 | $86,732 | 115 | BAXTER HEALTHCARE ($36,285) |
| 2018 | $95,770 | 92 | BAXTER HEALTHCARE ($50,042) |
| 2017 | $51,738 | 86 | BAXTER HEALTHCARE ($35,316) |
All Payment Transactions
477 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Baxter Healthcare | Renal - Acute (Device) | Food and Beverage | In-kind items and services | $102.78 | General |
| Category: Renal | ||||||
| 12/16/2024 | Nuwellis, Inc. | Aquadex Smartflow Console (Device) | Food and Beverage | Cash or cash equivalent | $204.33 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Renal | ||||||
| 12/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Travel and Lodging | In-kind items and services | $245.10 | General |
| Category: Renal | ||||||
| 12/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Travel and Lodging | In-kind items and services | $228.64 | General |
| Category: Renal | ||||||
| 12/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Renal | ||||||
| 12/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Travel and Lodging | In-kind items and services | $22.00 | General |
| Category: Renal | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| 10/25/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | — | In-kind items and services | $67.93 | Research |
| Study: A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) • Category: NEPHROLOGY | ||||||
| 10/22/2024 | Mozarc Medical US LLC | CARPEDIEM (Device) | Food and Beverage | Cash or cash equivalent | $17.90 | General |
| Category: HEMATOLOGY | ||||||
| 10/21/2024 | Mozarc Medical US LLC | CARPEDIEM (Device) | Food and Beverage | Cash or cash equivalent | $24.31 | General |
| Category: HEMATOLOGY | ||||||
| 10/10/2024 | Baxter Healthcare | Renal - Acute (Device) | Food and Beverage | In-kind items and services | $110.82 | General |
| Category: Renal | ||||||
| 10/01/2024 | Fresenius USA Marketing, Inc. | CRIT-LINE (Device) | Honoraria | Cash or cash equivalent | $375.00 | General |
| Category: System, Hemodialysis, Access Recirculation Monitoring | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $58.61 | General |
| Category: Immunology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| 08/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: NEPHROLOGY | ||||||
| 07/19/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/19/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $73.94 | General |
| 07/02/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/18/2024 | Fresenius USA Marketing, Inc. | CRIT-LINE (Device) | Honoraria | Cash or cash equivalent | $250.00 | General |
| Category: System, Hemodialysis, Access Recirculation Monitoring | ||||||
| 06/12/2024 | Medtronic, Inc. | CARPEDIEM (Device) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: Hematology | ||||||
| 06/11/2024 | Fresenius USA Marketing, Inc. | CRIT-LINE (Device) | Honoraria | Cash or cash equivalent | $250.00 | General |
| Category: System, Hemodialysis, Access Recirculation Monitoring | ||||||
| 06/05/2024 | Baxter Healthcare | Renal - Acute (Device) | Education | Cash or cash equivalent | $5,270.00 | General |
| Category: Renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ADPKD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,790 | 2 |
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,375 | 3 |
| 1VIT15041 | Luitpold Pharmaceuticals Inc | $1,200 | 1 |
| 1VIT13036 | Luitpold Pharmaceuticals Inc | $1,050 | 1 |
| A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $67.93 | 1 |
About Dr. Stuart Goldstein, MD
Dr. Stuart Goldstein, MD is a Pediatric Nephrology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780764035.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Goldstein, MD has received a total of $421,287 in payments from pharmaceutical and medical device companies, with $51,678 received in 2024. These payments were reported across 477 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($115,194).
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location Cincinnati, OH
- Active Since 10/17/2006
- Last Updated 06/17/2010
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1780764035
Products in Payments
- Renal - Non Product Related (Biological) $95,610
- Renal - Acute (Device) $60,230
- TOLVAPTAN (Drug) $38,416
- Aquadex (Device) $20,676
- CRIT-LINE (Device) $19,849
- Renal - CRRT (Device) $13,606
- JYNARQUE (Drug) $12,306
- NephroCheck Test (Device) $10,025
- CARPEDIEM (Device) $9,689
- Critline - Monitors (Device) $8,370
- LIPOSORBER (Device) $7,268
- SAMSCA (Drug) $6,790
- Aquadex Smartflow Console (Device) $6,408
- Carnitor (Drug) $6,375
- Argyle (Device) $6,363
- AQUADEX SMARTFLOW CONSOLE (Device) $5,929
- Auryxia (Drug) $5,160
- Fluid Systems - Non Prod Related (Biological) $3,315
- Gammaplex 10% (Biological) $3,200
- Renal - HD (Device) $3,087
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in Cincinnati
Prasad Devarajan, M.d, M.D
Pediatric Nephrology — Payments: $79,184
Pediatric Nephrology $79,184
Hillarey Stone
Pediatric Nephrology — Payments: $5,121
Pediatric Nephrology $5,121
Kyle Mccracken, M.d., Ph.d, M.D., PH.D
Pediatric Nephrology — Payments: $122.85
Pediatric Nephrology $122.85
Mark Mitsnefes, M.d, M.D
Pediatric Nephrology — Payments: $109.80
Pediatric Nephrology $109.80
Elif Erkan, Md, MD
Pediatric Nephrology — Payments: $89.14
Pediatric Nephrology $89.14
Dr. Jean-Philippe Roy, Md, MD
Pediatric Nephrology — Payments: $50.48
Pediatric Nephrology $50.48